Gilead Sciences stock: December FDA date set for anito-cel
Published on 11/13/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGilead's next regulatory catalyst
- Gilead is awaiting a December FDA target date for its investigational anito-cel CAR T therapy in multiple myeloma.
- Third-quarter product sales rose 13%, while HIV product sales increased 18% year over year.
- Management raised full-year 2026 product-sales guidance after the quarterly update.
Gilead Sciences is heading toward a key regulatory milestone for an investigational cancer therapy as the U.S. biotech sector enters the final weeks of 2026. A Morningstar report carrying PR Newswire commentary said Gilead's Biologics License Application for anitocabtagene autoleucel, also called anito-cel, is under review by the Food and Drug Administration. The agency's PDUFA target action date is December 23, 2026.
Anito-cel is an investigational CAR T-cell therapy for patients with relapsed or refractory multiple myeloma. The date is a target for FDA action rather than a decision, so the outcome of the review remains uncertain. For investors, the milestone puts a late-stage pipeline event on the calendar after a quarter in which Gilead also highlighted growth in its established HIV business.
Growth broadens the pipeline story
Gilead reported third-quarter 2026 product sales of 8.3 billion US dollars, up 13% from the same period a year earlier. HIV product sales rose 18% to 6.2 billion US dollars. The figures give the regulatory event a commercial backdrop: the company is advancing a new oncology opportunity while its HIV franchise remains the larger reported growth driver in the cited update.
The company also raised its full-year 2026 product-sales outlook to 31.0 billion to 31.3 billion US dollars, compared with the previous range of 30.1 billion to 30.4 billion US dollars. The same update said Gilead had received FDA approval for Bixlenvo, a bictegravir and lenacapavir combination for adults with HIV who are virologically suppressed on a stable antiretroviral regimen.
Management described the third quarter as an exceptional period, citing the strongest year-over-year base-business growth in more than a decade and pointing to the breadth and durability of the portfolio. That statement is a company view, while the FDA target date remains an external regulatory timetable rather than a guarantee of approval.
Stock trades above Thursday close
Gilead Sciences stock traded at 154.36 euros on Lang & Schwarz at 15:42 CET on Thursday, November 12, 0.18% above the Xetra close of Thursday, November 12. The comparison uses the Xetra closing price of 154.08 euros.
Gilead Sciences stock at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Home exchange: Nasdaq
- Lang & Schwarz price: 154.36 euros at 15:42 CET on November 12, 2026
- Change versus Xetra close: 0.18%
- Xetra close: 154.08 euros on November 12, 2026
Investors now have two distinct near-term reference points: the December FDA timetable for anito-cel and the company's upgraded sales outlook. The regulatory event could clarify the next step for Gilead's multiple myeloma strategy, while the commercial figures keep attention on HIV sales execution and the durability of the existing portfolio.
The broader market backdrop can be followed through the S&P 500.
